X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2402) 2402
Publication (297) 297
Book Chapter (38) 38
Book Review (30) 30
Magazine Article (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hepatitis c virus (1314) 1314
index medicus (1277) 1277
hepatitis c (1182) 1182
direct-acting antivirals (1032) 1032
humans (989) 989
gastroenterology & hepatology (718) 718
antiviral agents - therapeutic use (698) 698
ribavirin (596) 596
antiviral agents (592) 592
hepatitis c, chronic - drug therapy (571) 571
hepatitis (555) 555
interferon (520) 520
sofosbuvir (477) 477
hcv (424) 424
male (403) 403
health aspects (402) 402
sustained virological response (398) 398
female (380) 380
infectious diseases (377) 377
hepacivirus - genetics (374) 374
middle aged (362) 362
genotype (357) 357
hepacivirus - drug effects (347) 347
cirrhosis (342) 342
therapy (330) 330
virus-infection (322) 322
infection (319) 319
drug therapy, combination (315) 315
treatment outcome (309) 309
direct-acting antiviral (305) 305
virus diseases (297) 297
direct-acting antiviral agents (295) 295
direct acting antivirals (284) 284
hepatitis c - drug therapy (277) 277
liver (277) 277
virology (256) 256
infections (254) 254
analysis (252) 252
patients (252) 252
adult (249) 249
care and treatment (246) 246
liver cirrhosis (243) 243
drug therapy (241) 241
biological response modifiers (239) 239
aged (233) 233
viruses (229) 229
genotype 1 infection (228) 228
sustained virologic response (217) 217
chronic hepatitis c (214) 214
hepatitis c, chronic - virology (211) 211
pharmacology & pharmacy (211) 211
hiv (190) 190
digestive system diseases (189) 189
hepatocellular carcinoma (187) 187
antiviral agents - adverse effects (185) 185
ribavirin - therapeutic use (184) 184
daclatasvir (182) 182
pegylated interferon (182) 182
antiviral agents - administration & dosage (177) 177
treatment-naive patients (177) 177
genotype 1 (172) 172
ledipasvir (171) 171
hcv infection (170) 170
protease inhibitors (169) 169
telaprevir (166) 166
immunology (163) 163
antiviral agents - pharmacology (159) 159
hepatitis c, chronic - complications (159) 159
hepatitis-c virus (159) 159
hepatology (159) 159
genotypes (157) 157
medical research (157) 157
prevalence (155) 155
plus ribavirin (152) 152
efficacy (149) 149
gastroenterology and hepatology (148) 148
liver transplantation (148) 148
genetic aspects (147) 147
medicine, experimental (145) 145
medicine & public health (144) 144
safety (141) 141
direct‐acting antivirals (139) 139
fibrosis (137) 137
genotype & phenotype (135) 135
microbiology (135) 135
hepatocellular-carcinoma (134) 134
risk factors (134) 134
chronic hepatitis-c (125) 125
epidemiology (125) 125
transplantation (124) 124
antiviral therapy (122) 122
boceprevir (120) 120
medicine, general & internal (119) 119
liver diseases (118) 118
simeprevir (117) 117
review (115) 115
treatment-naive (115) 115
mortality (114) 114
hepatitis c - virology (113) 113
recurrence (111) 111
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2257) 2257
Korean (62) 62
Spanish (37) 37
Hungarian (24) 24
Japanese (17) 17
French (16) 16
German (16) 16
Russian (8) 8
Chinese (2) 2
Italian (1) 1
Persian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Gastroenterology, ISSN 0016-5085, 2017, Volume 152, Issue 6, pp. 1578 - 1587
Journal Article
Liver International, ISSN 1478-3223, 07/2017, Volume 37, Issue 7, pp. 974 - 981
Background & Aims The aim of this study was to assess the efficacy and safety of direct‐acting antivirals (DAA)‐based antiviral therapies for HCV patients with... 
direct‐acting antiviral | stage 4‐5 chronic kidney disease | hepatitis C virus infection | meta‐analysis | meta-analysis | direct-acting antiviral | stage 4-5 chronic kidney disease | ASUNAPREVIR | RENAL-DISEASE | COMBINATION | DIALYSIS PATIENTS | PEGYLATED INTERFERON | GENOTYPE 1 INFECTION | HEMODIALYSIS | DACLATASVIR | GASTROENTEROLOGY & HEPATOLOGY | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Male | Renal Insufficiency, Chronic - complications | Time Factors | Adult | Female | Hepatitis C - complications | Renal Insufficiency, Chronic - diagnosis | Drug Therapy, Combination | Odds Ratio | Kidney - physiopathology | Hepacivirus - drug effects | Severity of Illness Index | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Renal Insufficiency, Chronic - physiopathology | Hepatitis C - diagnosis | Antiviral Agents - adverse effects | Hepatitis C - virology | Hepacivirus - growth & development | Aged | Sustained Virologic Response | Antiviral agents | Care and treatment | Chronic kidney failure | Hepatitis C virus | Health aspects | Analysis | Renal function | Ritonavir | Viruses | Disease control | Patients | Incidence | Confidence intervals | Hepatitis | Renal failure | Dialysis | Libraries | Kidney diseases | Safety | Hepatitis C | Kidney transplantation
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 6, pp. 1511 - 1522
Summary Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment... 
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Treatment | Resistance-associated variants | Ledipasvir | Interferon | Hepatitis C virus | Sofosbuvir | Direct-acting antivirals | Resistanceassociated variants | CHRONIC HCV | CHRONIC HEPATITIS-C | REAL-WORLD | PEGYLATED INTERFERON | DOUBLE-BLIND | GENOTYPE 1 INFECTION | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | DACLATASVIR PLUS SOFOSBUVIR | Uridine Monophosphate - administration & dosage | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Carbamates - administration & dosage | Simeprevir - administration & dosage | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Treatment Failure | Protease Inhibitors - administration & dosage | Fluorenes - administration & dosage | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferons - administration & dosage | Drug Resistance, Viral - genetics | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Development and progression | Protease inhibitors | Drug resistance | Hepatitis C | Proteases
Journal Article